Type 2 diabetes mellitus (DM) is a chronic metabolic disorder. The prevalence of type 2 DM has been drastically increasing all over the world. Type 2 DM is characterized by insulin insensitivity as a result of insulin resistance, decreasing insulin production, and eventual pancreatic beta-cell failure. Increased inflammatory markers from fat, and oxidative factors, have all been implicated in the pathogenesis of type 2 DM. Curcumin is a naturally occurring polyphenol isolated from the rhizomes of the Curcuma longa herb (turmeric), which possesses anti-oxidant, and anti-inflammatory anti-diabetic properties. The aim of this study is to evaluate the anti-inflammatory, anti-oxidant and anti-diabetic effects of Curcumin in a randomized double blind placebo controlled trial included subject (n=120) with criteria of type 2 DM. All subjects will randomly assigned to receive either Curcumin or placebo capsules twice a day for 3months. To assess anti-diabetic, anti-oxidant and anti-inflammatory effects of Curcumin, changes in serum parameters including FBS, fasting insulin, C-peptide, HbA1c, Superoxide dismutase (SOD), plasma Total Antioxidant Capacity (TAO), Malondialdehyde (MDA), C reactive protein (CRP), leptin, adiponectin, TNF-α, ghreline, glucagon like peptide 1 (GLP-1), aspartate transaminase (AST), alanine transaminase (ALT) and serum creatinine will be monitored at the baseline and after 3month of treatments. Finally, the results will be analyzed by SPSS 20 software.